Ex-FDA chief Crawford moves into private-sector lobbying role:
This article was originally published in Clinica
Former FDA commissioner Dr Lester Crawford has joined the Washington DC-based lobbying firm Policy Directions as senior counsel. Dr Crawford mysteriously resigned from his post in September only three months after Senate confirmation. He was embroiled in a controversy over whether he had politicised the agency for overruling staff and outside advisors by indefinitely postponing a decision on whether to grant Barr Laboratories' emergency contraceptive Plan B product OTC status. His sudden departure is still under investigation by the Health and Human Services department's inspector general. Policy Directions represents several food, drug and device clients, including Bausch & Lomb, Baxter Healthcare, Bayer Diagnostics, Genzyme, and Visx. To read more about lobbying, see www.healthcarelobbyist.com.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.